Sarepta shares drop as report says FDA almost rejected under-review gene therapy

Submitted by admin on April 14, 2023 - 10:16am

Source:

Yahoo/Reuters

News Tags:

Sarepta Therapeutics

FDA

gene therapy

DMD

Duchenne Muscular Dystrophy

Headline:

Sarepta shares drop as report says FDA almost rejected under-review gene therapy

snippet:

Sarepta Therapeutics Inc's shares fell as much as 19.4% premarket on Thursday as Stat News reported that the U.S. Food and Drug Administration's staff were inclined to reject the company's gene therapy which is currently under review.

Search form

You are here

Sarepta shares drop as report says FDA almost rejected under-review gene therapy

Sarepta shares drop as report says FDA almost rejected under-review gene therapy